NRIX · CIK 0001549595 · operating
Nurix Therapeutics is a clinical-stage biopharmaceutical company developing small molecule degraders and antibody therapies focused on oncology, immunology, and inflammatory diseases. The company's pipeline centers on targeted protein degradation technology, with lead candidates including NX-5948, an oral BTK degrader in Phase 2 trials for relapsed or refractory B-cell malignancies and autoimmune conditions, and NX-2127, another oral BTK degrader in Phase 1a/1b development. Additional programs include NX-1607, a CBL-B inhibitor for immuno-oncology indications in Phase 1a/1b, and NX-0479/GS-6791, an IRAK4 degrader for rheumatoid arthritis and inflammatory diseases.
The company has established strategic collaborations with major pharmaceutical partners including Gilead Sciences, Sanofi, and Pfizer for co-development and co-commercialization of multiple drug candidates. These partnerships provide both development support and potential commercialization pathways for its therapeutic programs.
Nurix operates with approximately 317 full-time employees and is headquartered in Brisbane, California. The company was incorporated in Delaware in 2009 and is publicly listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-3.05 | $-3.05 | -5.9% | |
| 2024 | $-2.88 | $-2.88 | -8.7% | |
| 2023 | $-2.65 | $-2.65 | +28.6% | |
| 2022 | $-3.71 | $-3.71 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-11-30 | 2026-01-28 | 0001549595-26-000016 | SEC ↗ |
| 2024-11-30 | 2025-01-28 | 0001549595-25-000016 | SEC ↗ |
| 2023-11-30 | 2024-02-15 | 0001549595-24-000025 | SEC ↗ |
| 2022-11-30 | 2023-02-09 | 0001549595-23-000021 | SEC ↗ |
| 2021-11-30 | 2022-01-28 | 0001564590-22-003007 | SEC ↗ |
| 2020-11-30 | 2021-02-16 | 0001564590-21-006071 | SEC ↗ |